113 related articles for article (PubMed ID: 20824009)
1. uPAR and HER2 Genes Are Usually Co-Amplified in Individual Breast Cancer Cells from Blood and Tissues.
Uhr J
Breast Care (Basel); 2008; 3(s2):16-19. PubMed ID: 20824009
[No Abstract] [Full Text] [Related]
2. RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells.
Li C; Cao S; Liu Z; Ye X; Chen L; Meng S
Int J Cancer; 2010 Oct; 127(7):1507-16. PubMed ID: 20063318
[TBL] [Abstract][Full Text] [Related]
3. HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer.
Indira Chandran V; Eppenberger-Castori S; Venkatesh T; Vine KL; Ranson M
Oncoscience; 2015; 2(3):207-24. PubMed ID: 25897424
[TBL] [Abstract][Full Text] [Related]
4. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
5. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
[TBL] [Abstract][Full Text] [Related]
6. Relationships of protein biomarkers of the urokinase plasminogen activator system with expression of their cognate genes in primary breast carcinomas.
Sereff SB; Daniels MW; Wittliff JL
J Clin Lab Anal; 2019 Nov; 33(9):e22982. PubMed ID: 31359505
[TBL] [Abstract][Full Text] [Related]
7. Profiling signalling pathways in formalin-fixed and paraffin-embedded breast cancer tissues reveals cross-talk between EGFR, HER2, HER3 and uPAR.
Berg D; Wolff C; Malinowsky K; Tran K; Walch A; Bronger H; Schuster T; Höfler H; Becker KF
J Cell Physiol; 2012 Jan; 227(1):204-12. PubMed ID: 21391216
[TBL] [Abstract][Full Text] [Related]
8. Droplet digital PCR using HER2/EIF2C1 ratio for detection of HER2 amplification in breast cancer tissues.
Tantiwetrueangdet A; Panvichian R; Wongwaisayawan S; Sueangoen N; Lertsithichai P
Med Oncol; 2018 Oct; 35(12):149. PubMed ID: 30284063
[TBL] [Abstract][Full Text] [Related]
9. Observer prediction of HER2 amplification in HercepTest 2+ breast cancers as a potential audit instrument.
Going JJ
Histopathology; 2011 Aug; 59(2):333-5. PubMed ID: 21884213
[TBL] [Abstract][Full Text] [Related]
10. Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry.
Davies V; Voutsadakis IA
Cancer Invest; 2020 Feb; 38(2):94-101. PubMed ID: 31977265
[No Abstract] [Full Text] [Related]
11. The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells - A data description.
Hongisto V; Aure MR; Mäkelä R; Sahlberg KK
Genom Data; 2014 Dec; 2():249-53. PubMed ID: 26484103
[TBL] [Abstract][Full Text] [Related]
12. The genomic profile of HER2-amplified breast cancers: the influence of ER status.
Marchiò C; Natrajan R; Shiu KK; Lambros MB; Rodriguez-Pinilla SM; Tan DS; Lord CJ; Hungermann D; Fenwick K; Tamber N; Mackay A; Palacios J; Sapino A; Buerger H; Ashworth A; Reis-Filho JS
J Pathol; 2008 Dec; 216(4):399-407. PubMed ID: 18810758
[TBL] [Abstract][Full Text] [Related]
13. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.
Morrison Joly M; Hicks DJ; Jones B; Sanchez V; Estrada MV; Young C; Williams M; Rexer BN; Sarbassov dos D; Muller WJ; Brantley-Sieders D; Cook RS
Cancer Res; 2016 Aug; 76(16):4752-64. PubMed ID: 27197158
[TBL] [Abstract][Full Text] [Related]
14. Urokinase receptor and resistance to targeted anticancer agents.
Gonias SL; Hu J
Front Pharmacol; 2015; 6():154. PubMed ID: 26283964
[TBL] [Abstract][Full Text] [Related]
15. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
16. HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment.
Risio M; Casorzo L; Redana S; Montemurro F
Oncol Rep; 2005 Feb; 13(2):305-9. PubMed ID: 15643516
[TBL] [Abstract][Full Text] [Related]
17. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Kalous O; Conklin D; Desai AJ; O'Brien NA; Ginther C; Anderson L; Cohen DJ; Britten CD; Taylor I; Christensen JG; Slamon DJ; Finn RS
Mol Cancer Ther; 2012 Sep; 11(9):1978-87. PubMed ID: 22761403
[TBL] [Abstract][Full Text] [Related]
18. Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients.
Pierga JY; Bonneton C; Magdelénat H; Vincent-Salomon A; Nos C; Boudou E; Pouillart P; Thiery JP; de Cremoux P
Int J Cancer; 2005 Mar; 114(2):291-8. PubMed ID: 15543615
[TBL] [Abstract][Full Text] [Related]
19. uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.
Huber MC; Mall R; Braselmann H; Feuchtinger A; Molatore S; Lindner K; Walch A; Gross E; Schmitt M; Falkenberg N; Aubele M
BMC Cancer; 2016 Aug; 16():615. PubMed ID: 27502396
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of the urokinase receptor splice variant uPAR-del4/5 in breast cancer cells affects cell adhesion and invasion in a dose-dependent manner and modulates transcription of tumor-associated genes.
Grismayer B; Sato S; Kopitz C; Ries C; Soelch S; Schmitt M; Baretton G; Krüger A; Luther T; Kotzsch M; Magdolen V
Biol Chem; 2012 Dec; 393(12):1449-55. PubMed ID: 23667902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
